Introduction
============

Renin Angiotensin System (RAS) is a hormonal system that regulates body fluid, electrolyte homostasis, and vascular tone ([@B174]; [@B147]). These classical functions of RAS are mediated by angiotensin effector peptides including Ang II, III and 1--7 ([@B9]). Ang II, the primary effector peptide, is produced in the blood and exerts a number of effects on kidney, adrenal glands, sympathetic nervous system and baroreceptor reflexes ([@B129]; [@B33]). Studies have also shown the presence of local RAS in many different tissues including brain ([@B54]; [@B166]; [@B163]; [@B61]; [@B47]). In the central nervous system, angiotensinogen is synthesized by astrocytes and subsequently cleaved by renin, angiotensin converting enzyme (ACE) and aminopeptidases or ACE2 and Neprilysin ([@B22]). Despite some speculations, it is not clearly known where these RAS enzymes are locally synthesized in the brain ([@B110]).

The angiotensin ligands interact with their receptors including angiotensin (AT) 1A, 1B, 2, 4 and Mas and controls various brain function ([@B62]; [@B126]). The receptors are differentially expressed in several parts of the brain ([@B88]; [@B23]). AT1A is expressed in areas mainly involved in regulation of blood pressure and electrolyte balance including subfornical organ, paraventricular nucleus of the hypothalamus, lateral septum, cerebral cortex, and hippocampus ([@B87]; [@B104]; [@B98]), brainstem baroreflex arc, olivocerebellary system, and preoptic region ([@B98]). While AT1B is expressed in structures which involve in higher brain function and memory including cerebral cortex and hippocampus ([@B87]).

Activation of AT1 receptors is associated with increase in oxidative stress ([@B128]), anxiety and stress ([@B135]; [@B170]), ischemic brain damage ([@B124]), and cognitive impairment ([@B117]).

AT2 receptor, on the other hand, is observed in parts of the brain which regulate learning and memory including hippocampus, cingulate cortex, superior colliculus, lateral septum, in thalamic nuclei, in the subthalamic nucleus, in the locus coeruleus, and in the inferior olive ([@B111]; [@B97]). AT2 receptor is also expressed in brain structures including red nucleus, pedunculopontine tegmental nucleus, bed nucleus of the supraoptic decussation, paragenual nucleus, motor hypoglossal nucleus, cerebellar nuclei ([@B144], [@B145]; [@B158]; [@B97]), substantia nigra ([@B56]; [@B161]), and ventral tegmental area ([@B56]). However, the extent of the receptor expression is limited after the fetal period ([@B3]). AT2 receptor signaling is suggested to play beneficial role in neurogenesis ([@B160]), cerebral blood flow ([@B83]; [@B51]), neuronal plasticity ([@B118]), and learning and memory ([@B86]). Activation of the receptor is also reported to attenuate inflammation ([@B130]), oxidative stress ([@B103]) and abnormal neuronal firing ([@B60]; [@B108]) observed as the result of AT1 receptor stimulation ([@B62]).

In addition to AT1 and AT2 receptors, recent evidences show the presence of other receptors in CNS including AT4 and Mas ([@B141]). AT4 receptor interacts with a different angiotensin ligand called angiotensin IV, and it is reported to regulate learning and memory in brain areas including the hippocampus, neocortex and motor nuclei ([@B172]; [@B30]). The receptor is also localized in claustrum, choroid plexus, pontine nucleus, thalamic nuclei, substantia nigra pars compacta and hypothalamus ([@B178]; [@B30]). It is also suggested for its neuroprotective effect against cerebral ischemia ([@B46]). Mas receptor also contributes for the diverse actions of RAS in the brain ([@B85]). The receptor is mainly localized in the hippocampus, amygdala, anterodorsal thalamic nucleus, cortex, and hypoglossal nucleus ([@B26]; [@B15]; [@B50]; [@B96]). Activation of the receptor by angiotensin 1--7 was found to strengthen synapses in areas involved in memory ([@B26]; [@B68]; [@B159]).

Brain RAS generally involves in regulating central activities including learning, memory, anxiety, depression, cognition, and emotional stress ([@B55]; [@B125]; [@B35]), but it also complements functions of the peripheral RAS ([@B110]). Importantly, there are growing evidence indicating the contribution of brain RAS in development of neurodegenerative disorders including AD ([@B176]; [@B154]; [@B2]; [@B8]; [@B151]). However, it is not exactly known how RAS system influences the development and progression of AD. It is not also well understood how medications acting on RAS system affect AD though some studies have shown a link between RAS and accumulation of toxic Aβ peptides ([@B115]; [@B59]), tau phosphorylation ([@B154]), oxidative stress ([@B32]), mitochondrial dysfunction ([@B120]), neuroinflammation ([@B162]) and cholinergic dysfunction ([@B13]).

Amyloid and Alzheimer's Disease
===============================

Aβ~42~ and Aβ~40~ are the two-predominant Aβ-proteins that are highly susceptible for aggregation to form oligomers, protofibrils, and fibrils ([@B140]; [@B4]). Under normal physiological conditions, brain eliminates toxic peptides via enzymatic degradation, perivascular drainage and receptor-mediated efflux transport ([@B72]; [@B164]; [@B79]; [@B127]; [@B11]). Impairment of either of these clearance mechanisms may result in accumulation of Aβ peptide. The accumulation can cause neuronal membrane damage, an increase in oxidative stress, receptor-mediated alteration of signal transduction, alteration of membrane pore, increase in intracellular level of calcium ion and mitochondrial damage ([@B173]; [@B29]). These changes also trigger persistent loss of cholinergic projections to the neocortex ([@B149]).

Aβ deposition facilitates the formation of pathological phosphorylated tau proteins ([@B28]; [@B175]; [@B21]). Accumulation of toxic tau protein could also occur independent of amyloid β ([@B90]). The abnormal aggregation and deposition of tau protein can result in formation of neurofibrillary tangles leading to a progressive loss of neurons ([@B25]; [@B65]; [@B171]). Tau mediated neurodegeneration could be due to sequestration of tau protein and disturbance of microtubule function ([@B6]; [@B81]). This results impairment of normal axon flow and subsequent loss of neurons and their connectivity ([@B81]; [@B10]).

Renin Angiotensin System and Aβ Peptides: *In Vitro* Studies
============================================================

*In vitro* studies have shown the role of ACE in the degradation of Aβ peptides halting the halts development of amyloid plaque ([@B78]; [@B121]). The enzymatic action of ACE in the breakdown Aβ peptides have demonstrated by several studies ([@B69]; [@B148]; [@B180]). Whilst ACE inhibitors were reported to promote Aβ aggregation ([@B78]). ACE2, a homolog of ACE, was also reported to have a catalytic role in the cleavage of Aβ~43~ to Aβ~40~ and this was inhibited by specific ACE2 inhibitor called DX600 ([@B102]). N domain part of the enzyme was found responsible for hydrolysis Aβ peptides at N-terminal position. ACE hydrolyses the most neurotoxic peptides Aβ~43~ and Aβ~42~ ([@B167]; [@B24]), in to amyloid peptides that are less susceptibility to aggregate and form senile plaques. ACE also metabolizes the most abundant amyloid peptide, Aβ~40~ with the potential to reduce the Aβ~42~ oligomerization and deposition ([@B92]; [@B116]). ACE reduces amyloid β peptides the main risk factor for the development and progression of AD ([@B89]) (**Table [1](#T1){ref-type="table"}**). These studies altogether indicate the metabolic action of RAS enzymes in reducing amyloid plaque deposition via degradation of the most toxic form amyloid peptides composed of 40-43 amino acid sequences.

###### 

The effect of ACE-Is on Amyloid-β level: *In vitro* study.

  Cloned culture   Effects of ACE expression                 Effects of ACE inhibition                      Reference
  ---------------- ----------------------------------------- ---------------------------------------------- ----------------
  Seminal plasma   Decrease Aβ~40~ level                     Lisinopril promote Aβ~40~ production           Hu e/al., 2001
  Neuroblastoma    Decrease Aβ~40~ and Aβ~42~ level          Captopril promote Aβ~40~ and Aβ~42~ level      [@B69]
  HEK293           Increase break down of Aβ~43~ to Aβ~42~   DX600 inhibit breakdown Aβ~43~ to Aβ~42~       [@B102]
  COS7 cells       Increase breakdown of Aβ~40~              **--**                                         [@B121]
  CHO cells        Increase breakdown of m and h Aβ          **--**                                         [@B148]
  COS7 cells       Increase breakdown of Aβ~42~ to Aβ~40~    ACEIs inhibit conversion of Aβ~42~ to-Aβ~40~   [@B180]
                                                                                                            

ACEIs, angiotensin converting enzyme inhibitors; CHO, Chinese hamster ovary; HEK, human embryonic kidney cells 293; Aβ, Amyloid-β; m Aβ, murine Amyloid- β; h Aβ, human amyloid- β.

Renin Angiotensin System and Alzheimer's Disease: Animal Studies
================================================================

*In vitro* studies have shown the role of ACE in degradation of Aβ peptides thereby reducing deposition and accumulation of amyloid plaque while inhibition of the enzyme is detrimental ([@B69]; [@B148]; [@B180]; [@B102]). Ramipril (ACE inhibitor) also increased Aβ peptides in ACE10/10 mice with AD ([@B18]). Recent studies, however, does not support the idea that ACEIs increases accumulation of Aβ peptides in AD animal models ([@B40]; [@B70]; [@B48], [@B49]). These studies challenge the notion that ACEIs inhibit degradation of Aβ peptides and favoring amyloid plaque formation. Some ACEIs even reduced Aβ peptide level in animal models of AD ([@B2]). Moreover, ACEIs showed beneficial effect in reducing AD signs and symptoms ([@B39]; [@B157]; [@B1]). Administration of perindopril (ACEI) has shown an instrumental effect in increasing density of normal neurons and improving learning and memory ([@B76]). A study on Tg2576 AD model demonstrated the positive role of captopril in preventing signs of neurodegeneration ([@B2]). These studies support the potential benefit of ACEIs in alleviating sign and symptom of AD; however, with contrasting reports. A study on Tg2576 mice showed increase in deposition of Aβ~42~ after treatment with captopril ([@B181]). In line with this study, treatment with ramipril elevated brain level of Aβ~42~ peptide in AD^+^ACE (10/10) mice. Most *in vivo* studies have shown a positive correlation between increased expression of ACE and signs of AD but ACE inhibitors have protective effect against AD (**Table [2](#T2){ref-type="table"}**). The protective effect of ACE inhibitors could be explained partly via suppressing brain derived neurotrophic factor decline and TNF-α release. They were also found to ameliorate oxidonitrosative stress and nitrotyrosine production ([@B5]) with that in turn reduces amyloidogenesis and subsequent Aβ deposition ([@B57]). However, further investigations are required to see if the contradicting reports were intrinsic to the specific inherent nature of the drug or methodological issue.

###### 

The effect of ACEIs on Brain A level: Animal studies.

  Animal model                 Tested drug           Results                                  Reference
  ---------------------------- --------------------- ---------------------------------------- -----------
  Aβ~42~ induced SDR           Perindopril           Decrease Aβ~42~                          [@B76]
  Tg2576 mice                  Captopril/Enalapril   Reduced Aβ plaque and ROS accumulation   [@B2]
  C57BL/6 × DBA2 and 3xTg AD   Captopril             No effect on Aβ levels                   [@B70]
  LPS induced Mice             Perindopril           Decrease Aβ level                        [@B5]
  LPS induced WRs              Perindopril           Decrease Aβ levels and improved CBF      [@B57]
  A E10/10 mice                Ramipril              Increase Aβ levels                       [@B18]
                                                                                              

ACE, angiotensin converting enzyme; LPS, lipopolysaccharide; ROS, reactive oxygen species

.

A review by Kehoe indicated Ang II (as with ACE) increased accumulation and deposition Aβ peptides in AD animal models ([@B91]). Ang II increases Aβ level, promotes cerebrovascular dysfunction, and micro-vascular amyloid deposition which those in turn worsens AD outcome ([@B45]). ARBs, e.g., telmisartan, have shown to prevent cognitive decline associated with Aβ~40~ injection ([@B113]). Olmesartan was also associated with improved cognitive function and hippocampal synaptic plasticity ([@B153]). Losartan was reported to prevent neuropathological and cognitive deficits observed in AD ([@B123]). These studies showed the beneficial roles of ARBs in animal models of AD. The protective effect could be explained in part via suppressing AT1 receptor mediated APP mRNA up regulation, Aβ peptide production and phosphorylated tau induced neurotoxicity ([@B176]). The protective effect of these drugs could also be attributed as a result of unopposed action of Ang II on AT2 receptor ([@B75]; [@B53]) and stimulation of AngIV/AT4R signaling as observed in losartan ([@B131]). AT2 receptor mediated signaling pathways are known to prevent degeneration of neurons ([@B99]; [@B109]). In line with these reports, valsartan have shown to attenuate oligomerization of Aβ peptides into high molecular weight oligomeric peptides and reduces cognitive deterioration ([@B165]). However, other studies with the same model have shown that Aβ induces the formation of oligomers of AT2 receptor in the hippocampus that disrupts Ang II mediated signaling. The Aβ- induced AT2 receptor oligomerization was associated with enhanced neurodegeneration. Conversely, inhibition of cross-linked AT2 receptor delayed tau phosphorylation ([@B3]).

In other studies, however, valsartan or eprosartan (ARBs), did not alter accumulation of Aβ oligomers and phosphorylated tau in triple transgenic mice ([@B48]). The contradiction could be reconciled by the difference in AD animal models used. Variability in the dose of drug, the age and strain of animal used in the experiment could also explain the discrepancy ([@B49]). Despite varying result of RAS on amyloidosis, the overall effects of this system seem to favor amyloidosis. More specifically, the Ang II favors production of Aβ peptides via the most widely expressed angiotensin receptor, AT1 ([@B73]). In addition to reduction of Aβ deposition and its consequences, RAS inhibitors have also other beneficial roles including suppression of inflammation ([@B133]), oxidative stress ([@B128]), vascular damage/ischemia ([@B152]), and increase in acetylcholine release ([@B13]) and glutamate uptake ([@B132]) (**Figure [1](#F1){ref-type="fig"}**).

![Ang-II induces oxidative stress, inflammation and vascular disease via AT1R. Consequently, it causes accumulation of amyloid-β resulting Alzheimer's disease. However, AT2 R signaling produces beneficial effect including learning and memory. ARBs inhibit AT1R signaling and this shifts the action of Ang-II toward the beneficial pathway (AT2R signaling). ACEIs, Angiotensin converting enzyme inhibitors; ARBs, Angiotensin Receptor blockers; AT1R, Angiotensin 1 Receptor; AT2R, Angiotensin 2 Receptor; Aβ, Amyloid-β; -, negative outcome or blockage; +, positive outcome.](fphar-09-00440-g001){#F1}

Ang II enhances AT1 receptor mediated brain inflammation. Contrarily, ARBs attenuates the release of proinflammatory mediators ([@B95]). Central infusion of Ang II increased hippocampal CD68- positive cells, indicating its hippocampal proinflammatory action ([@B151]). In contrarily, candesartan (ARB) decreased lipopolysaccharide (LPS) induced and AT1 receptor mediated release of proinflammatory mediators including TNFα, IL-1β, IκBα, iNOS, ICAM-1, and VCAM-1 in cerebral cortex ([@B17]). In addition, candesartan attenuated brain level of NF-α, GFAP, COX-2, and NF-κB in the same animal model. They have also demonstrated the advantage of unopposed action of Ang II on AT2 receptor in addition to AT1 receptor blockage mediated amelioration of proinflammatory mediators releasesuggesting the beneficial role of AT2 receptors in reducing neuroinflammation ([@B58]). Moreover, ARBs prevents impairment and preserves the integrity of blood brain barrier which in turn reduces infiltration of inflammatory mediators observed in many neurodegenerative disease including AD ([@B38]; [@B124]; [@B143]).

AngII via AT1 receptor is also suggested as effector of oxidative stress ([@B119]; [@B105]; [@B31]; [@B138]; [@B128]). Ang II increased a reactive oxygen species called superoxide ([@B151]). On the other hand, telmisartan (ARB) was found to normalize diminished thioredoxin (Trx) system in addition to attenuating thioredoxin-interacting protein (TXNIP) expression. This reduces generation of endogenous reactive oxygen species ([@B44]). Similarly, telmisartan reduced advanced glycation end products and 4-hydroxynonenal, which are the markers of oxidative stress and associated with Neurodegeneration ([@B136]; [@B14]). Candesartan also reduced brain level of free radicals by diminishing Malondialdehyde and increasing glutathione level ([@B156]). Thus partly alleviates the development and progression of AD ([@B63]; [@B137]). Captopril ([@B19]) and losartan ([@B139]) were also found to ameliorate oxidative stress.

Ang II is also implicated in neurovascular damage and cognitive impairment ([@B112]; [@B22]; [@B20]). Candesartan increased cerebral blood flow, reduced infarct size and improved cerebral ischemia ([@B82]; [@B43]). Similarly, losartan prevented blood brain barrier disruption and restored blood flow after induction of hemorrhagic stroke. Moreover, telmisartan ([@B84]), valsartan ([@B150]), and olmesartan ([@B106]) have shown a beneficial role in prevention of vascular damage via blockage of AT1 receptor. Suggested mechanism of ARBs on cerebral blood flow is in part explained via unblocked AT2 receptor activation ([@B83]; [@B99]; [@B86]). These studies generally show the benefit of ARBs in improving neurovascular network and cerebral blood flow after certain initial insult which in turn prevents onset and progressive neurodegeneration observed in AD ([@B16]; [@B179]). In addition to the above mechanisms described, Ang II is also speculated to inhibit acetylcholine release in which the deficiency is responsible for AD ([@B12]; [@B155]). Conversely, pre-treatment with candesartan prevented Ang II induced reduction of acetylcholine level ([@B156], [@B155]). This reduces cognitive impairment observed in AD ([@B27]; [@B71]).

Renin Angiotensin System and Alzheimer's Disease: Human Studies
===============================================================

Human studies have shown the involvement of RAS in the pathogenesis and progression of AD ([@B7]; [@B93]). Nevertheless, only few studies have shown a link between RAS and AD ([@B42]; [@B34]). ACEIs and ARBs have shown a beneficial effect in slowing and reducing the cognitive impairment associated with AD ([@B101]; [@B77]; [@B134]). In a cross sectional study, patients taking ARBs and ACEIs had lower risk of cognitive deterioration ([@B85]).

Central acting RAS inhibitors have shown a superior efficacy which imply brain RAS involvement in development and progression of AD ([@B66]; [@B146]; [@B168]; [@B177]). A prospective multicentre cohort study showed slower rate of cognitive decline on older adults taking ACE-Is ([@B146]). ARBs and ACEIs were generally found to reduce the risk and progression of AD ([@B64]; [@B100]; [@B34]). The central acting agent including perindopril was significantly associated with a slower rate of functional decline ([@B34]). Telmisartan reduced cognitive impairment in hypertensive patients with AD ([@B101]). The drug reduced amyloid β, oxidative stress and neuroinflammation. The RAS also activates peroxisome proliferator activated receptor (PPAR) gamma which has a role in prevention of neurodegeneration ([@B80]; [@B94]; [@B101]). Other ARBs losartan ([@B114]; [@B74]), and olmesartan ([@B107]) have shown beneficial effect in AD patients. In contrast, in a 4-month of pilot clinical trial ramipril was not associated with reduction of CSF Aβ~1-42~ level and cognitive impairment ([@B169]). This limited effect of ramipril could be attributed to its limited blood brain barrier penetration ([@B142]). Most of these studies support the beneficial effect of RAS inhibitors in prevention and mitigation of cognitive impairments associated with AD (**Table [3](#T3){ref-type="table"}**).

###### 

The effect of ACEIs and ARBs on cognitive function: Human study.

  Study design      Tested drug       Result                                             Reference
  ----------------- ----------------- -------------------------------------------------- -----------
  Cross sectional   ACE-Is and ARBs   Reduce cognitive decline                           [@B42]
  Observational     ACEIs             Slow decline of memory and daily functions         [@B64]
  Case Control      ACE-Is and ARBs   Decease incidence of AD                            [@B34]
  Cohort            ARBs              Reduction in the incidence and progression of AD   [@B100]
  Cohort            ACE-Is            Slow cognitive decline                             [@B146]
  Observational     RAS-Ms            Slows cognitive decline                            [@B168]
  Observational     CACE-Is           Reduce functional decline                          [@B122]
  Cohort            ACEIs             Not effect on cognitive decline                    [@B177]
                                                                                         

ACEIs, angiotensin converting enzyme inhibitors; ARBs, angiotensin II Receptor Blockers; RAS-Ms, renin angiotensin system medications; CACE-I, centrally acting Angiotensin converting enzyme inhibitors.

Genetic Studies
===============

Genetic studies have also reported for the associate of ACE with AD ([@B41]). ACE protein is coded by several genes containing various variants, specifically the insertion/deletion variant (rs1799752) have been associated with AD. Some other variants, including single nucleotide polymorphisms rs4291A \> T located 240 base pair from the initiation codon, and rs4343G \> A encoding a silent mutation in exon 16 were also thought to be involved in AD ([@B67]; [@B52]). AD patients with the haplotype of rs1800764 (CC): rs4291 (TT) responded better for ACEIs that can cross the blood brain barrier (captopril or perindopril). However, the response was not significant among independent carriers of rs1800764 or rs429 ([@B36]). Further stratification showed the benefit of ACEIs among ACE haplotypes (rs1800764 -- T and rs4291 -- A) and Apolipoprotein (APOE4) -- carriers (rs1800764 -- T or rs4291 -- T). Nevertheless, APOE4+ carriers were non-responsive for ACEIs indicating the role of genetic variation and ACEIs response rate among AD patients ([@B37]).

Conclusion
==========

Understanding AD in terms of various pathophysiological pathways is worthwhile to unravel the complex nature of the disease process and identifying potential therapeutic targets. The brain RAS is reported to be involved in the development and progression of AD through AT1 receptor via increasing the production of amyloid-β, oxidative stress, inflammatory processes, and decreasing release of acetylcholine. However, RAS also is reported to have protective effect against AD. Through AT2 receptor activation that counterbalances the deleterious effects of AT1 receptor mediated RAS effects. With concept, beneficial effect of ARBs against AD is via the unopposed action of Ang II on AT2 receptors it as AT1 receptor is blocked these drugs increased Ang II concentration to act on AT2 receptor. ACE is reported to be involved in breakdown of amyloid β peptides, but most of the studies have contradicting result. This requires further understanding especially involvement of ACE in cleavage of amyloid β peptides *in vivo*. In summary, RAS through AT1 receptor is linked with AD pathology through its action on neurovascular change, oxidative stress, and inflammation as evidenced by the protective role of ARBs and ACEIs both in patients and animal models. However, the role of RAS in AD pathology is still not well established and need further in-depth understanding.
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